Department of Molecular Biology, Rowan-Virtua School of Translational Biomedical Engineering & Sciences, Rowan University, Stratford, New Jersey, United States of America.
Department of Molecular Biology, Rowan-Virtua School of Osteopathic Medicine, Rowan University, Stratford, New Jersey, United States of America.
PLoS One. 2024 Jun 24;19(6):e0305000. doi: 10.1371/journal.pone.0305000. eCollection 2024.
Human sirtuin-2 (SIRT2) has emerged as an attractive drug target for a variety of diseases. The enzyme is a deacylase that can remove chemically different acyl modifications from protein lysine residues. Here, we developed a high-throughput screen based on a homogeneous time-resolved fluorescence (HTRF) binding assay to identify inhibitors of SIRT2's demyristoylase activity, which is uncommon among many ligands that only affect its deacetylase activity. From a test screen of 9600 compounds, we identified a small molecule that inhibited SIRT2's deacetylase activity (IC50 = 7 μM) as well as its demyristoylase activity (IC50 = 37 μM). The inhibitor was composed of two small fragments that independently inhibited SIRT2: a halogenated phenol fragment inhibited its deacetylase activity, and a tricyclic thiazolobenzimidazole fragment inhibited its demyristoylase activity. The high-throughput screen also detected multiple deacetylase-specific SIRT2 inhibitors.
人类 Sirtuin-2(SIRT2)已成为治疗多种疾病的有吸引力的药物靶点。该酶是一种去酰基酶,可以从蛋白质赖氨酸残基上去除化学上不同的酰基修饰。在这里,我们开发了一种基于均相时间分辨荧光(HTRF)结合测定的高通量筛选方法,以鉴定 SIRT2 的脱豆蔻酰基酶活性抑制剂,这在许多仅影响其脱乙酰基酶活性的配体中并不常见。从 9600 种化合物的测试筛选中,我们鉴定出一种小分子,它抑制 SIRT2 的脱乙酰基酶活性(IC50=7 μM)和脱豆蔻酰基酶活性(IC50=37 μM)。抑制剂由两个独立抑制 SIRT2 的小分子片段组成:卤代苯酚片段抑制其脱乙酰基酶活性,三环噻唑并苯并咪唑片段抑制其脱豆蔻酰基酶活性。高通量筛选还检测到多种脱乙酰基酶特异性 SIRT2 抑制剂。